Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354250 · ClinicalTrials.gov registry record · Phase 2
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00354250: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00354250 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00354250, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase II trial is studying how well ispinesib works in treating patients with metastatic or unresectable kidney cancer. Ispinesib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG ispinesib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354250
The ClinicalTrials.gov registry entry for NCT00354250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ispinesib is the first listed.
NCT00354250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354250 about?
NCT00354250 is a clinical study titled "Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer". This phase II trial is studying how well ispinesib works in treating patients with metastatic or unresectable kidney cancer. Ispinesib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00354250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00354250?
The interventions under investigation include: ispinesib (DRUG).
Who is sponsoring clinical trial NCT00354250?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.